KBP Biosciences Announces Support of Kidney Disease Clinical Trialists 2024 Workshop
Mar 27, 2024

SINGAPORE, 27 March 2024 -- KBP Biosciences PTE. Ltd. (“KBP Biosciences” or the “Company”), a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the global market, today announced that it is a proud corporate supporter of the Kidney Disease Clinical Trialists 2024 Workshop held in Washington DC, March 15-16, 2024. Invited speaker Fred Yang PhD, Chief Development Officer at KBP, presented “Combination Therapy for Patients with Complicated Disease Burden” and perspective on the Treatment for Multiple Symptoms/Composite Outcome with Balanced Safety Profile. 



(Photo: Fred Yang PhD, Chief Development Officer at KBP)


The presentation by Dr. Yang provided insights on how CKD patients with a complicated clinical presentation may benefit from combination therapy including RAS blockers, SGLT2 inhibitors, nonsteroidal MRAs, and GLP-1 receptor agonists. These modalities target multiple pathologic mechanisms including metabolic dysregulation, hemodynamic perturbations, and inflammation in patients with hypertension, diabetes, dyslipidemias, and other cardiorenal disorders. 


Advanced CKD patients have a high and complicated disease burden, limited viable treatment options, and may progress to ESRD and dialysis if not managed effectively. Combination therapy with currently available medications targeting a varied pathogenesis is emerging as standard of care in these patients. 


“Combination therapy for patients with a complicated disease burden represents an audacious attempt to address the high unmet medical need of patients with advanced CKD,” stated Professor Patrick Rossignol, KDCT Workshop Director, Head of the medical Specialties & Nephrology-Hemodialysis Departments at the Princess Grace Hospital (Monaco) & FCRIN INI-CRCT network coordinator. “It is an emerging approach to standard of care which providers should consider when determining best therapies for patients with advanced CKD.”


“KBP will continue to work with physicians and patients to find the best treatment options for patients with CV and CKD disease,” added Dr. Fred Yang, Chief Development Officer of KBP. 


About Kidney Disease Clinical Trialists 2024 Workshop

The Kidney Disease Clinical Trialists (KDCT) Workshop was a high-level think tank, with an exceptional expert faculty. It involved a limited number of attendees (100) and included distinguished nephrologists, clinical trialists, principal investigators and statisticians from academia, R&D pharma and device companies, patients, NIH, EMA, PMDA, FDA, and payers. The KDCT Workshops aim to foster an international exchange of ideas where we brainstorm on trial design, conduct, ethics, interpretation, approvability, and implementation encompassing drugs, devices, biomarkers and therapeutic strategies for kidney disease. Our objectives are to produce relevant data from controlled kidney disease clinical trials that will contribute to better clinical care and to understand the problems associated with making decisions about what constitutes relevant information, how to improve kidney disease clinical trials, and, as is commonly the case, how to satisfy regulatory authorities and payers.


About KBP Biosciences

KBP Biosciences is a global, clinical-stage biotechnology company, headquartered in Singapore, focused on discovering, developing, and commercializing innovative small-molecule therapeutics for the treatment of serious cardiorenal disease with large unmet medical needs. KBP Biosciences is engaged by its partner in developing a treatment for patients with uncontrolled hypertension and stage 3b/4 CKD. CLARION-CKD, a global Phase 3 clinical trial, is currently being conducted and expected to complete by the end of 2024.



For more information about KBP Biosciences, please visit the company website at https://www.kbpbiosciences.com/




Investor Relations:



Public Relations: